KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Ten-Year Outcomes of a Phase 3, Multicenter, Randomized Controlled Trial (SHIP0804) With 3-Month Neoadjuvant Androgen Deprivation Prior to 125I-Seed Transperineal Prostate Brachytherapy Followed by Nil Versus 9-Month Adjuvant Hormonal Therapy in Patients With Intermediate-Risk Prostate Cancer.

Wataru Fukuokaya, Kenta Miki, Manabu Aoki, Hiroyuki Takahashi, Shiro Saito, Atsunori Yorozu, Takashi Kikuchi, Takushi Dokiya, Shin Egawa, SHIP Collaborative Group

Int J Radiat Oncol Biol Phys 121(4) 875-884

PMID39551103
PMCID-
DOI10.1016/j.ijrobp.2024.11.010
发表日期2024-11-17
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

PURPOSE: To analyze the effects of adjuvant hormonal therapy (AHT) on time to event after neoadjuvant androgen deprivation therapy (ADT) and 125I-transperineal prostate brachytherapy (TPPB), compared with neoadjuvant ADT and TPPB only, in patients with intermediate-risk prostate cancer (IRPC). METHODS AND MATERIALS: In this multicenter, open-label, phase 3 randomized controlled trial (SHIP0804), 421 patients with IRPC were randomly assigned to either 9-month AHT (AHT arm) or no AHT (non-AHT arm) after 3 months of neoadjuvant ADT and TPPB. The primary endpoint was biochemical progression-free survival, and secondary endpoints included overall survival and clinical progression-free survival. Prostatic biopsy results 36 months after treatment were evaluated in a correlative investigation (SHIP36B). RESULTS: With a median follow-up of over 11 years, the 10-year biochemical progression-free survival rates were comparable: 82.9% in the AHT group and 78.4% in the non-AHT group (P = .51). Results were consistent across key prognostic indicators such as age at randomization, baseline prostate-specific antigen level, clinical stage, Gleason grade group, number of National Comprehensive Cancer Network intermediate-risk factors, and prostatic volume. The secondary endpoints, including overall survival and clinical progression-free survival, were also comparable between the 2 arms. Grade 3 or higher adverse events occurred in 5.4% and 1.4% of patients in the AHT and non-AHT arms, respectively. At 36-month post-TPPB prostate biopsy, only 3.1% of biopsied patients tested positive for residual tumors. There were no deaths due to prostate cancer in either group. CONCLUSIONS: Adding 9-month AHT to TPPB after 3-month neoadjuvant ADT did not improve long-term outcomes in patients with IRPC. These findings suggest that moderate-term AHT may not offer substantial benefits and thus should not be considered a standard treatment in this population with IRPC.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。